Yeon Jean Cho

Yeon Jean Cho

Auto-generated profile, based on publicly available information

Yeon Jean Cho

Department of Obstetrics and Gynecology, Samsung Jeil Women’s Clinic, Busan, Republic of Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Reproductive Toxicology
Verified
Journal Article
Closed access
YCYeon Jean Cho
Yeon Jean Cho
SPSeung Bin Park
Seung Bin Park
JPJung Woo Park
Jung Woo Park
SOSo Ra Oh
So Ra Oh
MHMyoungseok Han
Myoungseok Han

1 June 2019 in Clinical and Experimental Reproductive Medicine
Verified
Journal Article
Open access
PDF file
SOSo Ra Oh
So Ra Oh
SCSun Yi Choe
Sun Yi Choe
YCYeon Jean Cho
Yeon Jean Cho
Anti-Müllerian hormone (AMH), a peptide growth factor of the transforming growth factor-β family, is a reliable marker of ovarian reserve. Regarding assisted reproductive technology, AMH has been efficiently used as a marker to predict ovarian response to stimulation. The clinical use of AMH has recently been extended and emphasized. The uses of AMH as a predictive marker of menopause onset, diagnostic tool for polycystic ovary syndrome, and assessment of ovarian function before and after gynecologic surgeries or gonadotoxic agents such as chemotherapy have been investigated. Serum AMH levels can also be affected by environmental and genetic factors; thus, the effects of factors that may alter AMH test results should be considered. This review summarizes the findings of recent studies focusing on the clinical application of AMH and factors that influence the AMH level and opinions on the use of the AMH level to assess the probability of conception before reproductive life planning as a "fertility test."

YKYu-Mi Kim
Yu-Mi Kim
JCJin-Young Chung
Jin-Young Chung
HAHyun Sook An
Hyun Sook An
SPSung Yong Park
Sung Yong Park
BKByoung-gwon Kim
Byoung-gwon Kim
YHYoung-seoub Hong
Young-seoub Hong
With rising concerns of heavy metal exposure in pregnancy and early childhood, this study was conducted to assess the relationship between the lead, cadmium, mercury, and methylmercury blood levels in pregnancy and neonatal period. The study population included 104 mothers and their children pairs who completed both baseline maternal blood sampling at the second trimester and umbilical cord blood sampling at birth. The geometric mean maternal blood levels of lead, cadmium, total mercury, and methylmercury at the second trimester were 1.02 ± 1.39 µg/dL, 0.61 ± 1.51 µg/L, 2.97 ± 1.45 µg/L, and 2.39 ± 1.45 µg/L, respectively, and in the newborns, these levels at birth were 0.71 ± 1.42 µg/dL, 0.01 ± 5.31 µg/L, 4.44 ± 1.49 µg/L, and 3.67 ± 1.51 µg/L, respectively. The mean ratios of lead, cadmium, total mercury, and methylmercury levels in the newborns to those in the mothers were 0.72, 0.04, 1.76, and 1.81, respectively. The levels of most heavy metals in pregnant women and infants were higher in this study than in studies from industrialized western countries. The placenta appears to protect fetuses from cadmium; however, total mercury and methylmercury were able to cross the placenta and accumulate in fetuses.

1 January 2020 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
YCYeon Jean Cho
Yeon Jean Cho
JYJeong Hye Yun
Jeong Hye Yun
SKSu Jin Kim
Su Jin Kim
HKHyun Young Kwon
Hyun Young Kwon
Nonpersistent endocrine disrupting chemicals (npEDCs) are exogenous chemicals or mixtures of industrial agents that can interfere with the normal action of hormone with a shorter half-life and lower liposolubility. These are commonly found in plastics, medical equipment, detergents, and cosmetics. Recently, role of npEDCs on the changes of ovary and/or uterus development and alterations in hormonal signaling has been emphasized. However, many controversial results exist on the effects of npEDCs and reproductive health of women. Thus, we have focused to review the scientific evidence of a causal relationship between exposure to npEDCs and representative female reproductive issues such as menstrual cycle, endometriosis, uterine fibroids, polycystic ovarian syndrome and infertility/subfertility. Though not all studies indicated a positive correlation of npEDCs with female reproductive issues, the reviewed data illustrated that the majority of the available data strengthen the evidence of reproductive health-related actions of npEDCs. In future, recommendations should be made in order to reduce human exposure to npEDCs and to protect from steadily increasing reproductive health risks.

4 August 2022 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
HKHyun Young Kwon
Hyun Young Kwon
SPSeung Bin Park
Seung Bin Park
MHMyoungseok Han
Myoungseok Han
JPJung-Woo Park
Jung-Woo Park
YLYongmin Lee
Yongmin Lee
YCYeon Jean Cho
Yeon Jean Cho
ObjectiveTriphenyl phosphate (TPHP) is one of the most commonly used organophosphorus flame retardants that may accumulate in the environment. However, its effects on human reproductive organs have not been well studied. We aimed to investigate the in vitro effects of TPHP in human Ishikawa endometrial cancer cells to elucidate how TPHP exposure disrupts intracellular signaling and cell proliferation in reproductive tissues.MethodsHuman Ishikawa endometrial cancer cells were exposed to TPHP.ResultsExposure to TPHP elevated the levels of estrogen receptor (ER) α and progesterone receptor-B and reduced ER β in human Ishikawa endometrial cancer cells. TPHP stimulated phosphoinositide 3-kinase/protein kinase B and mitogenactivated protein kinase/ extracellular signal-regulated kinases 1/2 kinase signaling, which may contribute to the activation of ER function and induce nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in human Ishikawa endometrial cancer cells. Activated ER and NF-κB stimulate the expression of cyclin D1/ cyclin-dependent kinase (CDK) 4/CDK6, indicating cell cycle progression and proliferation.ConclusionThis report may provide new information on the molecular mechanisms underlying how TPHP exposure dysregulates the cellular physiology of the human endometrium.

4 December 2019 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
SLSEUNG HYUN LEE
SEUNG HYUN LEE
JBJong Woon Bae
Jong Woon Bae
MHMyoungseok Han
Myoungseok Han
YCYeon Jean Cho
Yeon Jean Cho
JPJung‑Woo Park
Jung‑Woo Park
YLYongmin Lee
Yongmin Lee
The aim of the present study was to compare the oncological outcome of nerve‑sparing radical hysterectomy (NSRH) and conventional radical hysterectomy (CRH) for early‑stage cervical cancer using a meta‑analysis. A systematic review and meta‑analysis was conducted, including 4 randomized controlled trials (RCT), 8 case‑control and 11 comparative cohort studies comparing the morbidity, pelvic dysfunctions and oncological outcome between the two surgical methods. A total of 23 studies were included in this meta‑analysis. The studies reported data of patients affected by cervical cancer; were written in English; included ≥20 patients; and reported data of patients with a comparison of clinical outcomes between NSRH and CRH. Data were extracted and risk of bias was assessed by four independent reviewers. A total of 1,796 patients were included: 884 patients (49.2%) undergoing NSRH and 912 (50.8%) undergoing CRH. The meta‑analyses were conducted using Review Manager version 5.3 software, which is designed for conducting Cochrane reviews. As regards perioperative parameters, NSRH was found to be associated with a lower intraoperative blood loss and a shorter length of hospital stay in comparison with CRH. Patients undergoing NSRH experienced lower incidence of urinary, colorectal and sexual dysfunction compared with patients undergoing CRH. However, the resected parametrial width was favorable in patients with CRH, suggesting that NSRH was inferior to CRH in terms of radicality. The 5‑year disease‑free and overall survival rates were similar between the two groups. In this systematic review and meta‑analysis, the collected data to date demonstrated that the nerve‑sparing approach guarantees minimized surgical‑related pelvic dysfunction, with similar oncological outcomes as CRH. However, further RCTs should be conducted to confirm the superiority and safety of NSRH.